Zoetis (ZTS) Company Overview

At the end of the last trading day, Zoetis (ZTS) was priced at $172.24, which represents a 0.17% increase compared to the day before.

Zoetis (ZTS) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.

In the most recent trading session, Zoetis (ZTS) finished at $165.02, which is an increase of 0.94% compared to the previous day.

In the most recent trading session, Zoetis (ZTS) finished at $165.02, which is an increase of 0.94% compared to the previous day.

TROY, Mich., Jan. 7, 2025 /PRNewswire/ -- A new report from Zoetis has raised questions among investors about whether the company's stock price is too high.

The Wall Street Journal published an article stating that Zoetis' OA pain medication, Librela, is unsafe. I discuss these claims and share my reasons for thinking they are not valid. Although Librela may soon have a change in its label, I believe there is no cause for concern, and I explain my reasoning.

Zoetis (ZTS) finished the last trading day at $164.84, which is an increase of 0.81% compared to the day before.

Two companies that match this description are Idexx Laboratories (NASDAQ: IDXX) and Zoetis (NYSE: ZTS), both of which specialize in animal healthcare. Idexx is already a key investment for my daughter, while Zoetis is one of my own, and I believe that gradually increasing your investment in successful companies is a smart strategy, as suggested by David Gardner, co-founder of Motley Fool. Although Idexx and Zoetis have dropped 37% and 28% from their highest values, they have still outperformed the S&P 500 in total returns over the last ten years.

The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.